References
[1] Hu C. Grants supporting research in China. Eur Heart J
2018;39:2342-4.
[2] Hu C. Emergency Protective Measures and Strategies of Covid-19:
From Lifestyle to Traditional Chinese Medicine. Clin Complement Med
Pharmacol 2023;3:100089.
[3] Wang X, Hu D, Dang S, et al. Efficacy and Safety of Shensong
Yangxin Capsules for Frequent VPCs in Congestive Heart Failure Study
Group. Effects of Traditional Chinese Medicine Shensong Yangxin Capsules
on Heart Rhythm and Function in Congestive Heart Failure Patients with
Frequent Ventricular Premature Complexes: A Randomized, Double-blind,
Multicenter Clinical Trial. Chin Med J (Engl) 2017;130:1639-47.
[4] Hua W, Gao RL, Zhao BC, et al. The Efficacy and Safety
of Wenxin Keli in Patients with Frequent Premature Ventricular
Contractions: A Randomized, Double-blind, Placebo-controlled,
Parallel-group, Multicenter Trial. Chin Med J (Engl) 2015;128:2557-64.
[5] Xu Y, Li X, Zhang H, et al. China Tongxinluo Study for
myocardial protection in patients with Acute Myocardial Infarction
(CTS-AMI): Rationale and design of a randomized, double-blind,
placebo-controlled, multicenter clinical trial. Am Heart J
2020;227:47-55.
[6] Li X, Zhang J, Huang J, et al. Efficacy and Safety of Qili
Qiangxin Capsules for Chronic Heart Failure Study Group. A multicenter,
randomized, double-blind, parallel-group, placebo-controlled study of
the effects of qili qiangxin capsules in patients with chronic heart
failure. J Am Coll Cardiol 2013;62:1065-72.
[7] Cardiac Arrhythmia Suppression Trial (CAST) Investigators.
Preliminary report: effect of encainide and flecainide on mortality in a
randomized trial of arrhythmia suppression after myocardial infarction.
N Engl J Med 1989;321:406-12.
[8] The SPRINT Research Group. A randomized trial of intensive
versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.
[9] Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure
lowering in intermediate-risk persons without cardiovascular disease. N
Engl J Med 2016;374:2009-20.
[10] Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to
Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension:
A Systematic Review and Meta-Analysis. Hypertension 2021;77:692-705.
[11] Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium
difficile infection. Nat Rev Dis Primers 2016;2:16020.
[12] Rezzoagli C, Archetti M, Mignot I, Baumgartner M, Kümmerli R.
Combining antibiotics with antivirulence compounds can have synergistic
effects and reverse selection for antibiotic resistance in Pseudomonas
aeruginosa. PLoS Biol 2020;18:e3000805.
[13] De Oliveira DMP, Bohlmann L, Conroy T, et al. Repurposing a
neurodegenerative disease drug to treat Gram-negative
antibiotic-resistant bacterial sepsis. Sci Transl Med 2020;12:eabb3791.
[14] Rodriguez B, Carusi A, Abi-Gerges N, et al. Human-based
approaches to pharmacology and cardiology: an interdisciplinary and
intersectorial workshop. Europace 2016;18:1287-98.
[15] Thille AW, Muller G, Gacouin A, et al. Effect of Postextubation
High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal
Oxygen Alone on Reintubation Among Patients at High Risk of Extubation
Failure: A Randomized Clinical Trial. JAMA 2019;322:1465-75.
[16] Yancy WS Jr, Crowley MJ, Dar MS, et al. Comparison of Group
Medical Visits Combined With Intensive Weight Management vs Group
Medical Visits Alone for Glycemia in Patients With Type 2 Diabetes: A
Noninferiority Randomized Clinical Trial. JAMA Intern Med 2020;180:70-9.
[17] Glenn AJ, Lo K, Jenkins DJA, et al. Relationship Between a
Plant-Based Dietary Portfolio and Risk of Cardiovascular Disease:
Findings From the Women’s Health Initiative Prospective Cohort
Study. J Am Heart Assoc 2021;10:e021515.
[18] Glenn AJ, Boucher BA, Kavcic CC, et al. Development of a
Portfolio Diet Score and Its Concurrent and Predictive Validity Assessed
by a Food Frequency Questionnaire. Nutrients 2021;13:2850.
[19] Writing Committee for the REMAP-CAP Investigators; Lawler PR,
Derde LPG, van de Veerdonk FL, et al. Effect of Angiotensin-Converting
Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ
Support-Free Days in Patients Hospitalized With COVID-19: A Randomized
Clinical Trial. JAMA 2023;329:1183-96.
[20] Volpp KG, Troxel AB, Mehta SJ, et al. Effect of Electronic
Reminders, Financial Incentives, and Social Support on Outcomes After
Myocardial Infarction: The HeartStrong Randomized Clinical Trial. JAMA
Intern Med 2017;177:1093-101.
[21] Varghese GM, Dayanand D, Gunasekaran K, et al. INTREST Trial
Investigators. Intravenous Doxycycline, Azithromycin, or Both for Severe
Scrub Typhus. N Engl J Med 2023;388:792-803.
[22] Choueiri TK, Powles T, Albiges L, et al. COSMIC-313
Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell
Carcinoma. N Engl J Med 2023;388:1767-78.
[23] Eichhorst B, Niemann CU, Kater AP, et al. GCLLSG, the HOVON and
Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and
Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic
Lymphocytic Leukemia. N Engl J Med 2023;388:1739-54.
[24] Encarnación-Rosado J, Sohn ASW, Biancur DE, et al. Targeting
pancreatic cancer metabolic dependencies through glutamine antagonism.
Nat Cancer 2023; doi: 10.1038/s43018-023-00647-3.
[25] Tian J, Chen JH, Chao SX, et al. Combined PD-1, BRAF and MEK
inhibition in BRAFV600E colorectal cancer: a phase 2
trial. Nat Med 2023;29:458-66.
[26] Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy
for pancreatic cancer. Nat Rev Clin Oncol 2023;20:318-37.
[27] Eisinger S, Sarhan D, Boura VF, et al. Targeting a scavenger
receptor on tumor-associated macrophages activates tumor cell killing by
natural killer cells. Proc Natl Acad Sci U S A 2020;117:32005-16.
[28] Berindan-Neagoe I, Braicu C, Irimie A. Combining the
chemotherapeutic effects of epigallocatechin 3-gallate with
siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects.
Int J Nanomedicine 2012;7:6035-47.
[29] Yip HYK, Papa A. Signaling Pathways in Cancer: Therapeutic
Targets, Combinatorial Treatments, and New Developments. Cells
2021;10:659.
[30] Shi X, Shu L, Wang M, et al. Triple-Combination Immunogenic
Nanovesicles Reshape the Tumor Microenvironment to Potentiate
Chemo-Immunotherapy in Preclinical Cancer Models. Adv Sci (Weinh)
2023:e2204890.
[31] Adams S, Diamond JR, Hamilton E, et al. Atezolizumab Plus
nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast
Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA
Oncol 2019;5:334-42.
[32] Delgado-Waldo I, Contreras-Romero C, Salazar-Aguilar S, et al.
A triple-drug combination induces apoptosis in cervical
cancer-derived cell lines. Front Oncol 2023;13:1106667.
[33] Menden MP, Wang D, Mason MJ, et al. Community assessment to
advance computational prediction of cancer drug combinations in a
pharmacogenomic screen. Nat Commun 2019;10:2674.
[34] Eduati F, Utharala R, Madhavan D, et al. A microfluidics
platform for combinatorial drug screening on cancer biopsies. Nat Commun
2018;9:2434.
[35] Gao P, Chang X, Zhang D, et al. Synergistic integration of
metal nanoclusters and biomolecules as hybrid systems for therapeutic
applications. Acta Pharm Sin B 2021;11:1175-99.
[36] Fu Y, Si A, Wei X, et al. Combining a machine-learning derived
4-lncRNA signature with AFP and TNM stages in predicting early
recurrence of hepatocellular carcinoma. BMC Genomics 2023;24:89.
[37] Eduati F, Jaaks P, Wappler J, et al. Patient-specific logic
models of signaling pathways from screenings on cancer biopsies to
prioritize personalized combination therapies. Mol Syst Biol
2020;16:e8664.
[38] Nassar ZD, Mah CY, Centenera MM, et al. Fatty Acid Oxidation Is
an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90
Inhibition. Mol Cancer Res 2020;18:1500-11.
[39] Demko ZP, Sharpless KB. Preparation of 5-substituted
1H-tetrazoles from nitriles in water. Demko ZP, Sharpless KB. J Org Chem
2001;66:7945-50.
[40] Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on solid
phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed
1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem
2002;67:3057-64.
[41] Agard NJ, Prescher JA, Bertozzi CR. A strain-promoted [3 +
2] azide-alkyne cycloaddition for covalent modification of
biomolecules in living systems. J Am Chem Soc 2004;126:15046-7.
[42] WATSON JD, CRICK FH. Molecular structure of nucleic acids; a
structure for deoxyribose nucleic acid. Nature 1953;171:737-8.
[43] WILKINS MH, STOKES AR, WILSON HR. Molecular structure of
deoxypentose nucleic acids. Nature 1953;171:738-40.
[44] FRANKLIN RE, GOSLING RG. Molecular configuration in sodium
thymonucleate. Nature 1953;171:740-1.
[45] Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z. Synergistic targeted
therapy for acute promyelocytic leukaemia: a model of translational
research in human cancer. J Intern Med 2015;278:627-42.
[46] Mao J, Wang Y, Zhang W, et al. Long-term correction of
hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid
FVIII composed of the human heavy chain and the rat light chain. Front
Med 2022;16:584-95.
[47] Berg P, Sorensen MV, Rousing AQ, et al. Challenged Urine
Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane
Conductance Regulator Function in Cystic Fibrosis. Ann Intern Med
2022;175:1543-51.